MORF vs. PTGX, AKRO, XNCR, DAWN, DVAX, KNSA, TARO, RCUS, KURA, and ANIP
Should you be buying Morphic stock or one of its competitors? The main competitors of Morphic include Protagonist Therapeutics (PTGX), Akero Therapeutics (AKRO), Xencor (XNCR), Day One Biopharmaceuticals (DAWN), Dynavax Technologies (DVAX), Kiniksa Pharmaceuticals (KNSA), Taro Pharmaceutical Industries (TARO), Arcus Biosciences (RCUS), Kura Oncology (KURA), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical preparations" industry.
Protagonist Therapeutics (NASDAQ:PTGX) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and community ranking.
Protagonist Therapeutics has higher revenue and earnings than Morphic. Morphic is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
Protagonist Therapeutics received 183 more outperform votes than Morphic when rated by MarketBeat users. Likewise, 59.73% of users gave Protagonist Therapeutics an outperform vote while only 59.54% of users gave Morphic an outperform vote.
Morphic's return on equity of 43.42% beat Protagonist Therapeutics' return on equity.
98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 94.3% of Morphic shares are held by institutional investors. 5.0% of Protagonist Therapeutics shares are held by insiders. Comparatively, 28.1% of Morphic shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Protagonist Therapeutics presently has a consensus target price of $38.00, indicating a potential upside of 34.61%. Morphic has a consensus target price of $51.50, indicating a potential upside of 79.94%. Given Protagonist Therapeutics' higher probable upside, analysts plainly believe Morphic is more favorable than Protagonist Therapeutics.
In the previous week, Protagonist Therapeutics had 15 more articles in the media than Morphic. MarketBeat recorded 17 mentions for Protagonist Therapeutics and 2 mentions for Morphic. Morphic's average media sentiment score of 0.95 beat Protagonist Therapeutics' score of 0.82 indicating that Protagonist Therapeutics is being referred to more favorably in the media.
Protagonist Therapeutics has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500. Comparatively, Morphic has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.
Summary
Protagonist Therapeutics beats Morphic on 13 of the 16 factors compared between the two stocks.
Get Morphic News Delivered to You Automatically
Sign up to receive the latest news and ratings for MORF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MORF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
